دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
10-Year Follow-Up After Revascularization in Elderly Patients With Complex Coronary Artery Disease
MasafumiOnoMDabPatrick W.SerruysMD, PhDbcHironoriHaraMDabHideyukiKawashimaMDabChaoGaoMDbdRutaoWangMDbdKuniakiTakahashiMDaNeilO’LearyPhDbJoanna J.WykrzykowskaMD, PhDaeFaisalSharifMD, PhDbfJan J.PiekMD, PhDaScotGargMD, PhDgMichael J.MackMD, PhDhDavid R.HolmesMDiMarie-ClaudeMoriceMDjStuart J.HeadMD, PhDkArie PieterKappeteinMD, PhDkDaniel J.F.M.ThuijsMDk…YoshinobuOnumaMD, PhDb
doi : 10.1016/j.jacc.2021.04.016
Volume 77, Issue 22, 8 June 2021, Pages 2761-2773
The optimal revascularization strategy for the elderly with complex coronary artery disease remains unclear.
Revascularizing Complex CAD in Elderly Patients: The Coming-of-Age Story of Percutaneous Coronary Intervention?
Ravi S.HiraMD
doi : 10.1016/j.jacc.2021.04.023
Volume 77, Issue 22, 8 June 2021, Pages 2774-2776
Glycated Hemoglobin and Subclinical Atherosclerosis in People Without Diabetes
XavierRosselloPhDabcSergioRaposeiras-RoubinPhDadBelénOlivaMScaF?timaS?nchez-CaboPhDaJosé M.Garc?a-Ru?zMDabFranciscaCaimariPhDeJosé M.MendigurenPhDfEnriqueLara-PezziPhDabHéctorBuenoPhDaghLeticiaFern?ndez-FrieraPhDabijAntonioFern?ndez-OrtizPhDbklJavierSanzPhDablBorjaIbanezPhDabmValentinFusterPhDal
doi : 10.1016/j.jacc.2021.03.335
Volume 77, Issue 22, 8 June 2021, Pages 2777-2791
The metabolic injury caused by protein glycation, monitored as the level of glycated hemoglobin (HbA1c), is not represented in most risk scores (i.e., Systematic Coronary Risk Estimation or atherosclerotic cardiovascular disease risk scale).
Glycated Hemoglobin to Detect Subclinical Atherosclerosis in People Without Diabetes?
Raul D.SantosMD, PhDabMichael D.ShapiroDOcChristie M.BallantyneMDd
doi : 10.1016/j.jacc.2021.04.018
Volume 77, Issue 22, 8 June 2021, Pages 2792-2795
Moderate Aortic Stenosis in Patients With Heart Failure and Reduced Ejection Fraction
GuillaumeJeanMDaNicolas M.Van MieghemMD, PhDbTeaGegenavaMDcLennartvan GilsMD, PhDbJeremyBernardMSaMarcel L.GeleijnseMD, PhDbE. MaraVollemaMDcIkramEl AzzouziMScbErnestSpitzerMDbVictoriaDelgadoMD, PhDcJeroen J.BaxMD, PhDcPhilippePibarotDVM, PhDaMarie-AnnickClavelDVM, PhDa
doi : 10.1016/j.jacc.2021.04.014
Volume 77, Issue 22, 8 June 2021, Pages 2796-2803
The study investigators previously reported that moderate aortic stenosis (AS) is associated with a poor prognosis in patients with heart failure (HF) with reduced left ventricular ejection fraction (LVEF) (HFrEF). However, the respective contribution of moderate AS versus HFrEF to the outcomes of these patients is unknown.
Aortic Stenosis and LV Dysfunction: Not Everything in Moderation?
SammyElmariahMDNilay K.PatelMD
doi : 10.1016/j.jacc.2021.04.027
Volume 77, Issue 22, 8 June 2021, Pages 2804-2806
Systemic Sirolimus Therapy for Infants and Children With Pulmonary Vein Stenosis
Jay D.PatelMDaMichaelBrionesDObMansiMandhaniMBBSaShannonJonesMDaDivyaSutharMDaRosemaryGrayRNaJoellePettusMPHaCourtneyMcCrackenPhDaAmandaThomasMSPHaChristopher J.PetitMDa
doi : 10.1016/j.jacc.2021.04.013
Volume 77, Issue 22, 8 June 2021, Pages 2807-2818
Anatomic interventions for pulmonary vein stenosis (PVS) in infants and children have been met with limited success. Sirolimus, a mammalian target of rapamycin inhibitor, has demonstrated promise as a primary medical therapy for PVS, but the impact on patient survival is unknown.
In Search of the Holy Grail for Pediatric Pulmonary Vein Stenosis?
Lourdes R.PrietoMD
doi : 10.1016/j.jacc.2021.04.029
Volume 77, Issue 22, 8 June 2021, Pages 2819-2821
Thrombolysis In Myocardial Infarction (TIMI) Study Group: JACC Focus Seminar 2/8
Marc S.SabatineMD, MPHEugeneBraunwaldMD
doi : 10.1016/j.jacc.2021.01.060
Volume 77, Issue 22, 8 June 2021, Pages 2822-2845
In 1984, the National Heart, Lung, and Blood Institute (NHLBI) decided to study the efficacy and safety of the treatment of acute myocardial infarction with an emerging therapy, coronary thrombolysis, and thus the TIMI (Thrombolysis In Myocardial Infarction) Study Group was born.
Prevention of Pathological Atrial Remodeling and Atrial Fibrillation: JACC State-of-the-Art Review
Yi ChingChenPhDa?AleksandrVoskoboinikMBBS, PhDabcd?Andre LaGercheMBBS, PhDaefThomas H.MarwickMBBS, PhD, MPHabcdeJulie R.McMullenPhDadeg
doi : 10.1016/j.jacc.2021.04.012
Volume 77, Issue 22, 8 June 2021, Pages 2846-2864
Atrial enlargement in response to pathological stimuli (e.g., hypertension, mitral valve disease) and physiological stimuli (exercise, pregnancy) can be comparable in magnitude, but the diseased enlarged atria is associated with complications such as atrial fibrillation (AF), whereas physiological atrial enlargement is not.
Type 1 Brugada Pattern Is Associated With Echocardiography-Detected Delayed Right Ventricular Outflow Tract Contraction
FilippoTrevisanMDMatteoBertiniMD, PhDCristinaBallaMDGabrielePestelliMDAndreaLuisiMDVittorioSmarrazzoMDMariannaFarnèMDAlessandraFerliniMDFrancescaGualandiMDDonatoMeleMD
doi : 10.1016/j.jacc.2021.03.334
Volume 77, Issue 22, 8 June 2021, Pages 2865-2867
Diabetes Mellitus and Risk Stratification After Peripheral Artery Revascularization
Connie N.HessMD, MHSJulia WeleskiFuPhD, MPHJacobGundrumMSNancy M.Allen LaPointePharmD, MHSTracy Y.WangMD, MHS, MScR. KevinRogersMD, MScWilliam R.HiattMD†Marc P.BonacaMD, MPH
doi : 10.1016/j.jacc.2021.04.011
Volume 77, Issue 22, 8 June 2021, Pages 2867-2869
Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy
WenbingJiangPhDWeiZhaoMMHeHuangPhD
doi : 10.1016/j.jacc.2020.12.074
Volume 77, Issue 22, 8 June 2021, Pages 2869-2870
Reply: Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy
Thomas H.MarwickMBBS, PhD, MPHTomokoNegishiMDPaaladineshThavendiranathanMD, SMon behalf of theSUCCOUR investigators
doi : 10.1016/j.jacc.2021.04.006
Volume 77, Issue 22, 8 June 2021, Pages 2870-2871
Cardiogenic Shock, the Residual SYNTAX Score, and Prognosis: Corroborative “Real-World” Data
Sonya N.BurgessBSc, MBChBCraig P.JuergensMBBS, DMedScChristian J.MussapMBBS, PhDSidney T.H.LoMBBSJohn K.FrenchB Med SC, MBCHB, PhD, MSc
doi : 10.1016/j.jacc.2021.02.068
Volume 77, Issue 22, 8 June 2021, Pages 2871-2872
Could Residual SYNTAX Score Predict the Prognosis of Patients With Cardiogenic Shock?
XiaofeiLiMMShimaoNiMM
doi : 10.1016/j.jacc.2021.02.069
Volume 77, Issue 22, 8 June 2021, Page 2872
Reply: The Residual SYNTAX Score: A Useful Tool to Predict Outcomes in Cardiogenic Shock
OlivierBarthélémyMDStéphanieRouanetMSUweZeymerMDHolgerThieleMDGillesMontalescotMD, PhD
doi : 10.1016/j.jacc.2021.04.008
Volume 77, Issue 22, 8 June 2021, Pages 2872-2873
